Search

Your search keyword '"van der Ende ME"' showing total 145 results

Search Constraints

Start Over You searched for: Author "van der Ende ME" Remove constraint Author: "van der Ende ME"
145 results on '"van der Ende ME"'

Search Results

1. Maraviroc Pharmacokinetics in HIV-1–Infected Pregnant Women

2. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study

3. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

4. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women

5. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

6. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

7. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe

8. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in clinical practice in Europe

9. Low Prevalence of Cardiac Abnormalities in an HIV-Seropositive Population on Antiretroviral Combination Therapy

10. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

11. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study

12. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

13. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

14. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

15. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

16. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

17. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy

24. Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response

25. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients.

28. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

29. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

30. Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors.

31. Fendrix® compared to Engerix® in HIV-infected patients nonresponding to initial- and re-vaccination schedule.

32. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy.

33. Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy.

34. Reply to Darcis and Berkhout.

35. A longitudinal and cross-sectional study ofEpstein-Barr virus DNA load: a possible predictor of AIDS-related lymphoma in HIV-infected patients.

36. HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.

37. The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.

38. A mutation in the progesterone receptor predisposes to HEV infection in HIV-positive patients.

39. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age.

40. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

41. Risk factors in an HIV-infected population for refraining from specialist care.

42. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

43. Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

44. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

45. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study.

46. Low mother-to-child-transmission rate of Hepatitis C virus in cART treated HIV-1 infected mothers.

47. Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions.

49. von Willebrand Factor is elevated in HIV patients with a history of thrombosis.

50. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.

Catalog

Books, media, physical & digital resources